Consolidated statement of changes in equity

EXCEL format VIEW PAGE AS EXCEL [XLS - 26KB]



        Attributable to holders of the parent              
    Share
capital
R’000
  Share
premium
R’000
  Non-
distri-
butable
reserves
R’000
  Retained
income
R’000
  Total
attributable
ordinary
shareholders
R’000
  Non-
controlling
interest
R’000
  Total
R’000
 
  Balance at 30 September 2010 (audited) 17 365   1 190 290   349 061   1 357 939   2 914 655   158 685   3 073 340  
  Share issue 4   465           469       469  
  Movement in treasury shares (471)   (272 158)           (272 629)       (272 629)  
  Share-based payment expense                            
  – continuing operations         3 185       3 185       3 185  
  – discontinued operation         (831)       (831)       (831)  
  Subsequent acquisition of non-controlling interests in:                            
  – Ayrton Drug Manufacturing Limited             42   42   (69)   (27)  
  – Addclin Research (Pty) Limited             1 345   1 345   (1 345)      
  Disposal of business                     (12 644)   (12 644)  
  Total comprehensive income         (19 209)   353 361   334 152   6 915   341 067  
  Profit for the period             353 361   353 361   6 915   360 276  
  Other comprehensive income         (19 209)       (19 209)       (19 209)  
  Dividends             (177 157)   (177 157)   (21 045)   (198 202)  
  Balance at 31 March 2011 (unaudited) 16 898   918 597   332 206   1 535 530   2 803 231   130 497   2 933 728  
  Share issue 21   2 903           2 924       2 924  
  Movement in treasury shares (31)   (19 269)           (19 300)       (19 300)  
  Share-based payment expense         3 500       3 500       3 500  
  Acquisition through business combination                     14 072   14 072  
  Subsequent acquisition of non-controlling interests in Ayrton Drug Manufacturing Limited             (4 162)   (4 162)   (5 156)   (9 318)  
  Total comprehensive income         35 662   400 844   436 506   4 818   441 324  
  Profit for the period             400 844   400 844   3 680   404 524  
  Other comprehensive income         35 662       35 662   1 138   36 800  
  Dividends                     (6 607)   (6 607)  
  Distribution out of share premium     (136 943)           (136 943)       (136 943)  
 
Balance at 30 September 2011 (audited)
16 888   765 288   371 368   1 932 212   3 085 756   137 624   3 223 380  
  Share issue 45   5 031           5 076       5 076  
  Movement in treasury shares (41)   (25 509)           (25 550)       (25 550)  
  Share-based payment expense         9 069       9 069       9 069  
  Subsequent acquisition of non-controlling interests in Ayrton Drug Manufacturing Limited             (2 000)   (2 000)   (8 752)   (10 752)  
  Total comprehensive income         (42 050)   335 296   293 246   3 342   296 588  
  Profit for the period             335 296   335 296   6 427   341 723  
  Other comprehensive income         (42 050)       (42 050)   (3 085)   (45 135)  
  Dividends                     (1 280)   (1 280)  
  Distribution out of share premium     (183 831)           (183 831)       (183 831)  
  Balance at 31 March 2012 (unaudited) 16 892   560 979   338 387   2 265 508   3 181 766   130 934   3 312 700